Table 3. Real world effectiveness of camrelizumab-based therapy.

Variables	Total (n=403)
Best objective response, n (%)
Complete response	0 (0.0)
Partial response	116 (28.8)
Stable disease	206 (51.1)
Progressive disease	28 (6.9)
Not evaluated	53 (13.2)
Tumor response rate, % (95% CI)	28.8 (24.4–33.5)
Disease control rate, % (95% CI)	79.9 (75.7–83.7)

CI, confidence interval.